Join our daily newsletter At The Bell to receive exclusive market insights
- Medicinal cannabis company Incannex Healthcare (IHL) has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment
- OSA occurs when the airway at the back of the throat becomes blocked — when this occurs, loud snoring and choking noises are made
- As a result, the brain and body become oxygen deprived and the sleeper may wake up multiple times throughout the night
- The upcoming trial will assess the therapeutic benefit of Incannex’s IHL-42X treatment at three different dose levels
- The primary endpoint will be a reduction in the apnoea hypopnea index (AHI) compared to the baseline level
- Incannex is up 5.45 per cent on the market and shares are trading for 5.8 cents each
Medicinal cannabis company Incannex Healthcare (IHL) has received ethics approval for a phase 2b clinical trial investigating its obstructive sleep apnoea (OSA) treatment.
OSA occurs when the airway at the back of the throat becomes blocked. When this occurs, loud snoring and choking noises are made.
As a result, the brain and body become oxygen deprived and the sleeper may wake up multiple times throughout the night. This can cause high blood pressure, heart disease, stroke, depression, and diabetes.
Current treatments include weight loss, changing the sleeping position, surgery, and continuous positive airway pressure (CPAP).
The upcoming trial, which will be randomised, double-blind and placebo-controlled, will assess the therapeutic benefit of Incannex’s IHL-42X treatment at three different dose levels.
The primary endpoint will be a reduction in the apnoea hypopnea index (AHI) compared to the baseline leven.
The trial will take place at the Alfred Hospital in Melbourne under the supervision of principal investigator Terry O’Brien and contact research origination Novotech.
Patient enrolment will occur in the near future.
“The receipt of ethics approval to commence our first in-human clinical trial is a significant milestone for Incannex,” CEO and Managing Director Joel Latham commented.
“A successful drug treatment would be a paradigm shift in obstructive sleep apnoea considering low patient compliance to the current standard of care, the CPAP device,” he said.
Incannex is up 5.45 per cent and shares are trading for 5.8 cents at 10:51 am AEST.
